New Video Available: Monocytes & Sex Differences in Pain Duration

Published on September 2, 2026

New Video Available: How Monocyte-Derived IL-10 Drives Sex Differences in Pain Duration

Watch the full presentation now in the Media Center

In Episode 17 of the PURPOSE Professional Series, Geoffroy Laumet, PhD, and Sarah Linnstaedt, PhD, share translational research on how monocyte-derived IL-10 drives the resolution of inflammatory pain. Combining preclinical mouse models with clinical data from human traumatic injury cohorts, the speakers illustrate how a pro-resolving monocyte subset signals directly to sensory neurons to suppress hyperexcitability. They also explore how androgen signaling accounts for sex differences in pain duration and discuss the therapeutic potential of specialized pro-resolving mediators like resolvin D1.

Key Learnings:

  • Neuroimmune Silencing Mechanisms: How monocyte-derived IL-10 directly targets sensory neurons to calm hyperexcitability and accelerate pain resolution.

  • Hormonal Drivers of Sex Differences: How testosterone and androgen receptor signaling regulate monocyte abundance and IL-10 production.

  • Translational Clinical Relevance: How findings from rodent models align with human recovery data following traumatic injury.
Other news

FY25 Inclusion Data for NIH-Supported Clinical Research Now Available by NIH Spending Category

September 2, 2026
In May, we shared NIH-wide fiscal year (FY) 2025 enrollment data on the sex, race, ethnicity, and age of participants in NIH-supported clinical research, offering a broad view of inclusion across the NIH portfolio. More detailed FY25 enrollment data are now available through the NIH Research, Condition, and Disease Categorization (RCDC) Inclusion Statistics Report. The interactive report allows us

Electromagnetic neuromodulation for chronic pain: historical context, contemporary modalities, and evidence gaps

September 2, 2026
Front Pain Res (Lausanne). 2026 Aug 18;7:1901466. doi: 10.3389/fpain.2026.1901466. eCollection 2026.ABSTRACTElectromagnetic neuromodulation is increasingly used as an adjunct or alternative to pharmacologic therapy for pain, with several approaches cleared for select indications and many others under active investigation. We review implanted neuromodulation approaches (intracranial and spinal), va